Action

RET fusions

Alt Name

Approval Jurisdiction

2020 FDA

Approved for clinical use

NSCLC, MTC, thyroid cancers

Brutto

CAS

2152628-33-4

Commercial Vendor

Eli Lilly

Compound Image

Selpercatinib.png

Compound name

Selpercatinib

InChI

InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

InChI Key

XIIOFHFUYBLOLW-UHFFFAOYSA-N

MW

525.60

PubChem CID

134436906

Reference

Reference 2

SMILES

CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O

Approved Drug List

1